why does nobody talk about sequence
why does nobody talk about sequence. If this has been answered properly somewhere, link me and I will delete.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Sent a vial to VendorInvestigate: 98.3% against a claimed 97.5%, with the mass confirming the sequence. Both halves mattered to me.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
the tendon claims are the most repeated and the least evidenced